7TM Pharma completes positron emission tomography preclinical research program to successfully demonstrate peripheral restriction of its CB1 receptor antagonist TM38837
7TM Pharma receives milestone payment from asthma and allergy collaboration
A potential new treatment for cancer supportive care and gastrointestinal diseases